Sleep Disorders

Resource Center

FDA Alerts

Narcolepsy

FDA Approves Drug for Cataplexy, Excessive Daytime Sleepiness Associated With Narcolepsy

07/22/2020

The new drug is the first FDA-approved option for this indication in more than 15 years and contains significantly less sodium than a current standard-of-care option.

07/22/2020

Research Summaries

Research Summary

Patient Adherence to CPAP Treatment For Obstructive Sleep Apnea and Risk of Cardiovascular Events

02/02/2024

Jessica Ganga

Researchers conducted a systematic review to assess the effect of CPAP treatment for obstructive sleep apnea on secondary cardiovascular disease events.

02/02/2024

Research Summary

In Small Trial, FDA-Approved Insomnia Treatment Decreases Alzheimer Proteins in Healthy Adults

09/07/2023

Anthony Calabro, MA

Researchers found that patients taking suvorexant had reduced levels of amyloid beta and tau phosphorylation, proteins that play a major role in neurodegeneration in Alzheimer disease.

09/07/2023

Research Summary